Merck KGaA news

   Watch this stock
Showing stories 1 - 10 of about 103   

Articles published

MRK 98.76 -0.03 (-0.03%)
price chart
Merck KGaA to build new life science hub in Massachusetts
Germany's Merck KGaA has announced new plans to create a “major hub” for its North American life science business as it prepares to build a new campus in Burlington, MA, but will be leaving its former Billerica base.
Merck KGaA to build $115M Boston hub, aiming for a higher profile in ...  FiercePharma
MilliporeSigma Starts Construction on $115 Million Multi-faceted Life ...  PR Newswire (press release)
Merck KGaA, AmoyDx Partner on Colorectal Cancer Test for Chinese Market
NEW YORK (GenomeWeb) - Germany-basedMerck KGaA announced today that it has partnered with Amoy Diagnostics to develop and commercialize a liquid biopsy test for metastatic colorectal cancer for the Chinese market.
BRIEF-Germany's Merck KGaA, AmoyDx collaborate to bring liquid biopsy RAS ...
July 28 Merck KGaA : * Merck and Amoy Diagnostics Co Ltd collaborate to bring liquid biopsy RAS biomarker testing to China.
Merck KGaA (MRK) Given a €110.00 Price Target by Deutsche Bank AG Analysts
Merck KGaA logo Merck KGaA (FRA:MRK) has been given a €110.00 ($122.22) target price by analysts at Deutsche Bank AG in a research report issued on Thursday.
Broker Outlook For Merck KGaA (MKGAY)  Fiscal Standard
Are Analysts Bearish Merck KGaA (ETR:MRK) After Last Week?  Consumer Eagle
Merck KGaA doubles size of VC fund, bringing cap up to $340M
Merck KGaA has doubled the size of its venture capital fund. The funding boost, which raises the cap on the fund to €300 million ($340 million), is part of an expansion in the scope of the investment unit, which will now funnel money into companies ...
Merck KGaA loses FDA nod for fertility drug
It's been more than 10 years since the FDA signed off on Merck KGaA's fertility drug Luveris. But now, after the company failed to conduct a postmarketing trial, the FDA has yanked the drug's approval at the German pharma's request.
Merck KGaA puts a lead cancer drug on the chopping block, Threshold craters
The clinical misery at Merck KGaA is continuing unabated this week. The German pharma company reported early today that its cancer therapy TH-302 failed both Phase III studies, forcing it to abandon two indications while reconsidering its commitment to ...
Merck KGaA Drops Cancer Drug Development After Studies Fail  Bloomberg
Merck KGaA, Darmstadt, Germany, Decides Not to Pursue Evofosfamide Further ...  PR Newswire (press release)
Merck KGaA Expands in Metro Boston
Boston—Global technology company Merck KGaA, of Darmstadt, Germany, will build a new 30-acre campus near Routes 3 and 128 in Burlington, Mass.
Merck KGaA (OTCMKTS:MKGAY) Receives Average Recommendation of "Buy" from Analysts
Merck KGaA logo Shares of Merck KGaA (OTCMKTS:MKGAY) have been given a consensus recommendation of “Buy” by the twelve brokerages that are presently covering the company.
Merck KGaA blueprints fresh growth in Massachusetts R&D ops
After more than a decade stymied by one of the worst track records in biopharma R&D, Merck KGaA announced plans today to beef up its R&D operations in Massachusetts, adding 30,000 square feet of research space and new staffers to its research arm.